Successful Treatment of Vitiligo with Crisaborole 2% Ointment

Main Article Content

William Tausend
Paige Hoyer
Morgan Arnold
Keith Wagner
Lindy Ross
Brandon P Goodwin
Janice M Wilson


Vitiligo, crisaborole, PDE-4 inhibitor


Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment.

Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.


1. Huff S, Gottwald L. Repigmentation of Tenacious Vitiligo on Apremilast. Case Reports in Dermatological Medicine. 2017. DOI: 10.1155/2017/2386234

2. Kailas A. Crisaborole: a new and effective nonsteroidal topical drug for atopic dermatitis. Dermatologic Therapy. 2017;30(5). DOI: 10.1111/dth.12533

3. Eichenfield LF, Call RS, et al. “Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.” JAAD. 77(4), 2017 Oct

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)